Investigating the Effects of Cannabidiol on Social Anxiety Disorder
The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD).
| Condition(s) | Phobia, Social |
|---|---|
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Summary | The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD). |
| Who can participate | Inclusion Criteria: * Ability and willingness to provide written informed consent. * Sufficiently fluent in English to participate in the trial. * Between 18-55 years of age (inclusive). * Right-hand dominant. * Current medications are stable for past 30 days (no changes to dose or frequency). * Negative result on pregnancy test (if female). * Negative result on urine drug screening. * Liebowitz Social Anxiety Scale (LSAS ≥ 60). Exclusion Criteria: * History of bipolar disorder, schizophrenia, psychosis, delusional disorders. * History of eating disorder within past 6 months. * History of any traumatic brain injury. * Currently diagnosed with diabetes mellitus. * Presence of severe medical illness that would prevent completion of study procedures. * Presence of significant neurological ill |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Lead sponsor | Massachusetts Institute of Technology |
| Locations | Cambridge, Massachusetts, United States |
| Start date | 2025-07-10 |
| NCT ID | NCT05649059 |
| Official listing | https://clinicaltrials.gov/study/NCT05649059 |